Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD5 | P21918 | 1/20 | 0.69 |
| ▸ | SCNN1A | P37088 | 1/20 | 0.69 |
| ▸ | SCNN1B | P51168 | 1/20 | 0.69 |
| ▸ | SCNN1G | P51170 | 1/20 | 0.69 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.69 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18538920 | 0.93 | DRD5 (0.75) | DRD5SCNN1ASCNN1BSCNN1GHRH3 | |
| SCHEMBL18538919 | 0.90 | DRD5 (0.78) | DRD5SCNN1ASCNN1BSCNN1GHRH3 | |
| SCHEMBL20032722 | 0.87 | DRD5 (0.85) | DRD5SCNN1ASCNN1BSCNN1GHRH3 | |
| SCHEMBL18538897 | 0.86 | DRD5 (0.72) | DRD5SCNN1ASCNN1BSCNN1GHRH3 | |
| SCHEMBL20032721 | 0.86 | DRD5 (0.73) | DRD5SCNN1ASCNN1BSCNN1GHRH3 | |
| SCHEMBL18538924 | 0.85 | DRD5 (0.76) | DRD5SCNN1ASCNN1BSCNN1GHRH3 | |
| SCHEMBL20032719 | 0.85 | DRD5 (0.68) | DRD5SCNN1ASCNN1BSCNN1GHRH3 | |
| SCHEMBL20348260 | 0.84 | DRD5 (0.78) | DRD5SCNN1ASCNN1BSCNN1GHRH3 | |
| SCHEMBL18538901 | 0.84 | DRD5 (0.70) | DRD5SCNN1ASCNN1BSCNN1GHRH3 | |
| SCHEMBL18538902 | 0.83 | DRD5 (0.81) | DRD5SCNN1ASCNN1BSCNN1GHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180186774-A1 | NOVEL ANNELATED BENZAMIDES | BOEHRINGER INGELHEIM INT (DE) | 2018-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186774-A1 | NOVEL ANNELATED BENZAMIDES | HDAC10, HDAC11, H1-0 | DRD5 608/4885SCNN1A 667/4885SCNN1B 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.